Case-Based Roundtables on TargetedOnc.com are collaborative, small-group discussions about case-based clinical profiles and engaging peer-dialogue led by an expert physician. These resources offer practicing oncologists and hematologists insight on relevant data, treatment strategies, and varying professional opinions.

LATEST MULTIPLE MYELOMA CONTENT

Costa Explains What Drives Survival Benefit With Tec/Dara in Myeloma

Data Increasingly Favor BCMA-Directed Therapy For Early-Relapse Myeloma

Dosing and Toxicity Considerations for Heavily Pretreated Patients With Myeloma

Bridging Before CAR T in Myeloma Should Aim For Deep Response, Not Just Stability

Myeloma Physicians Consider Approaches to Subcutaneous Therapy

Considering the Applications of On-Body Injector for Myeloma in Community Practice

CARTITUDE-4 Data, IMWG Guideline Make the Case for Second-Line CAR T in Myeloma

Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy

CASE-BASED ROUNDTABLES

Emerging Multiple Myeloma Therapies and Sequencing Decisions

October 01, 2026

Using CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Treating Later-Line Multiple Myeloma With CAR T-Cell Therapy

February 23, 2024

Operationalization of Cancer Care in R/R Multiple Myeloma

October 26, 2023

Treatment Options in Patients With R/R Multiple Myeloma in the Later-Line Setting

September 27, 2023

Therapeutic Options for Patients With Multiple Myeloma in the Second Line and Beyond

Later-Line Combination Therapies Used as Treatment in Multiple Myeloma

Treating Relapsed/Refractory Multiple Myeloma With Bispecific Therapy

November 23, 2022

BCMA-Targeted Therapy in Patients with Multiple Myeloma

January 26, 2022

Using Anti-CD38 Monoclonal Antibodies as Treatment in Multiple Myeloma

January 07, 2022